- Home
- CAF vs VNDA Comparison
CAF vs VNDA Comparison
Compare CAF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAF
- VNDA
- Stock Information
- Founded
- CAF 2006
- VNDA 2002
- Country
- CAF United States
- VNDA United States
- Employees
- CAF N/A
- VNDA N/A
- Industry
- CAF Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CAF Finance
- VNDA Health Care
- Exchange
- CAF Nasdaq
- VNDA Nasdaq
- Market Cap
- CAF 218.7M
- VNDA 237.9M
- IPO Year
- CAF N/A
- VNDA 2006
- Fundamental
- Price
- CAF $12.68
- VNDA $4.35
- Analyst Decision
- CAF
- VNDA Strong Buy
- Analyst Count
- CAF 0
- VNDA 2
- Target Price
- CAF N/A
- VNDA $16.50
- AVG Volume (30 Days)
- CAF 63.6K
- VNDA 733.3K
- Earning Date
- CAF 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- CAF 1.02%
- VNDA N/A
- EPS Growth
- CAF N/A
- VNDA N/A
- EPS
- CAF N/A
- VNDA N/A
- Revenue
- CAF N/A
- VNDA $198,772,000.00
- Revenue This Year
- CAF N/A
- VNDA $14.36
- Revenue Next Year
- CAF N/A
- VNDA $44.53
- P/E Ratio
- CAF N/A
- VNDA N/A
- Revenue Growth
- CAF N/A
- VNDA 3.18
- 52 Week Low
- CAF $11.63
- VNDA $3.85
- 52 Week High
- CAF $14.38
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- CAF 50.50
- VNDA 44.06
- Support Level
- CAF $11.41
- VNDA $4.27
- Resistance Level
- CAF $12.55
- VNDA $4.46
- Average True Range (ATR)
- CAF 0.34
- VNDA 0.21
- MACD
- CAF 0.02
- VNDA 0.01
- Stochastic Oscillator
- CAF 66.76
- VNDA 71.64
About CAF Morgan Stanley China A Share Fund Inc.
Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.